In addition to being a senior investigator at the CHU de Quebec–Université Laval Research Center and professor in the Faculty of Pharmacy at Laval University, Dr. Di Paolo is also an associate professor at the University of Saskatchewan, Saskatoon, Canada. She received the Janssen-Ortho pharmaceutical research award from the Association of Faculties of Pharmacy of Canada (2002); the Heinz Lehmann prize from the Canadian College of Neuopsychopharmacology, 2003; distinctions: Femmes réussite region Chaudière Appalache, Journal Économique de Québec, 2004, Femme de mérite, YWCA of Québec, Science and technology category, 2006, Empreintes d’elles, YWCA, honoring 400 women, 400th anniversary of Québec City, 2008 and the Diamond prize for excellence in Fundamental Research, Centre Hospitalier Universitaire de Québec, Québec City, 2015.

Dr. Di Paolo has published over 295 peer-reviewed articles and 470 summaries. Her research interest is on Parkinson’s disease and L-Dopa-induced dyskinesias in the post-mortem human brains of Parkinson’s disease patients, non-human primates, and rodent models of Parkinson. This research was and is currently funded by the CIHR, NSERC, Parkinson Society Canada, CQDM, NIH and contracts from Prexton Therapeutics, Novartis, and Merck Serono. 

In recent years, her research has focused on the glutamatergic neurotransmission and the implication of ionotropic and metabotropic glutamate receptors. Various specific antagonists, positive and negative allosteric modulators of glutamate receptors were investigated to inhibit or prevent the development of L-Dopa-induced dyskinesias. Drugs of various pharmacological activities are also investigated in her laboratory including, serotoninergic drugs, omega-3, plasmalogens and dehydroepiandrosterone (DHEA). She recently investigated the effect of a subthalamic lesion on L-Dopa-induced dyskinesias in parkinsonian monkeys, and is now working on the effect of deep stimulation in this area of the brain.

A major research endeavour in her laboratory is also to investigate neuroprotection in a mouse model of Parkinson’s Disease. Repurposing drugs used to treat various endocrine conditions were found to be neuroprotective such as estrogen, progesterone, the selective estrogen receptor modulator raloxifene, and the 5α-reductase inhibitor, dutasteride. Novel non-genomic mechanisms of action were investigated in this neuroprotection, including the implication of the membrane estrogen receptor (GPER1) and the effect of cholesterol on membrane microviscosity.

CHUL
2705, boulevard Laurier
T2-50
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

278 entries « 1 of 28 »

Awogbindin IO, Ben-Azu B, Olusola BA, Akinluyi ET, Adeniyi PA, Di Paolo T, Tremblay MÈ

Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease.

Journal Article

Front Cell Neurosci, 15 , 2021.

Abstract | Links:

Awogbindin IO, Ishola IO, St-Pierre MK, Carrier M, Savage JC, Di Paolo T, Tremblay ME

Remodeling microglia to a protective phenotype in Parkinson's disease?

Journal Article

Neurosci Lett, 735 , 2020.

Abstract | Links:

Lecours C, St-Pierre MK, Picard K, Bordeleau M, Bourque M, Benadjal A, Gagnon D, Cantin L, Parent M, Di Paolo T, Tremblay ME, Awogbindin IO, Ibanez FG

Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease.

Journal Article

Brain Behav Immun, 90 , 2020.

Abstract | Links:

Jarras H, Bourque M, Poirier AA, Morissette M, Coulombe K, Di Paolo T, Soulet D

Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.

Journal Article

J Neuroendocrinol, 32 (1), 2020.

Abstract | Links:

Gasparini F, Di Paolo T

Drug repurposing: Old drugs, new tricks to fast track drug development for the brain.

Journal Article

Neuropharmacology, 147 , 2019.

| Links:

Bourque M, Morissette M, Di Paolo T

Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease.

Journal Article

Neuropharmacology, 147 , 2019.

Abstract | Links:

Nadeau J, Smith T, Lamontagne-Proulx J, Bourque M, Al Sweidi S, Jayasinghe D, Ritchie S, Di Paolo T, Soulet D

Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor.

Journal Article

Brain Res, 1725 , 2019.

Abstract | Links:

Gagnon D, Eid L, Coude D, Whissel C, Di Paolo T, Parent A, Parent M

Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys.

Journal Article

Front Neuroanat, 12 , 2018.

Abstract | Links:

Morissette M, Di Paolo T

Non-human primate models of PD to test novel therapies.

Journal Article

J Neural Transm (Vienna), 125 (3), 2018.

Abstract | Links:

Mosher LJ, Godar SC, Morissette M, McFarlin KM, Scheggi S, Gambarana C, Fowler SC, Di Paolo T, Bortolato M

Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Journal Article

Psychoneuroendocrinology, 91 , 2018.

Abstract | Links:

278 entries « 1 of 28 »
Signaler des ajouts ou des modifications

Active projects

  • Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing, from 2018-10-01 to 2023-03-31

Recently finished projects

  • Mechanisms of therapeutic efficacy of deep brain stimulation in Parkinson's disease, from 2015-07-01 to 2020-06-30
  • Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing, from 2018-04-01 to 2020-03-31
Data provided by the Université Laval research projects registery